Wang Xiaoling, Fang Honghao, Shen Kunling, Liu Tianyi, Xie Jipan, Liu Yuantao, Zhong Jia, Wu Eric, Zhou Wei, Wu Bin
Beijing Children's Hospital, Capital Medical University, Beijing, 100045, China.
Analysis Group, Beijing, 100022, China.
J Comp Eff Res. 2020 Nov 6. doi: 10.2217/cer-2020-0102.
To compare the cost-effectiveness of low-dose budesonide versus montelukast among patients aged 1-5 years from a Chinese patient and healthcare payer perspective. A Markov model based on exacerbation states was developed. Exacerbation was defined as the need for rescue therapy (mild exacerbation) or hoscopitalization (moderate-to-severe exacerbation). Inputs including efficacy (i.e., exacerbation rates), mortality, utilities, costs and treatment adherence were obtained from literature. Compared with montelukast, low-dose budesonide led to fewer exacerbation events (1.44 vs 2.15), lower costs (¥3675 vs 4130) and slightly more quality-adjusted life years (0.974 vs 0.967) over 1 year. These findings may improve the use of low-dose budesonide, an economically and clinically preferable treatment to montelukast in pediatric patients.
从中国患者和医疗支付方的角度比较低剂量布地奈德与孟鲁司特在1至5岁患者中的成本效益。开发了一种基于病情加重状态的马尔可夫模型。病情加重定义为需要急救治疗（轻度加重）或住院治疗（中度至重度加重）。从文献中获取包括疗效（即病情加重率）、死亡率、效用、成本和治疗依从性等输入数据。与孟鲁司特相比，在1年时间里，低剂量布地奈德导致的病情加重事件更少（1.44次对2.15次）、成本更低（3675元对4130元）且质量调整生命年略多（0.974对0.967）。这些发现可能会促进低剂量布地奈德的使用，在儿科患者中，它在经济和临床方面比孟鲁司特更具优势。
